Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $525.21 today based on a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy recommendation. Analyst Price Forecast Suggests 23.09% Upside As of March 4, 2025, the ...

Raymond James Financial Inc. bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the ...

Therefore, the Zacks rating upgrade for Krystal Biotech basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $218 from $212 and keeps a Buy rating on the shares after the company reported Q4 results and provided an update on the ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the shares following the Q4 report. The firm says the ...

NASDAQ:KRYS opened at $187.86 on Thursday. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The firm has a market capitalization of $5.41 billion, a price-to-earnings ...

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy? Shares of Exelixis, Inc. (NASDAQ: EXEL) have risen 20.7% in the past three months compared with the industry's growth of 6.3% ...

Krystal Integrated Services IPO price band has been fixed in the range of ₹680 to ₹715 per equity share of the face value of ₹10. (https://krystal-group.com ...

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...